| アブストラクト | INTRODUCTION: Non-exacerbating patients with chronic obstructive pulmonary disease (COPD) are a less studied phenotype. We investigated clinical characteristics, mortality rates and causes of death among non-exacerbating compared with exacerbating patients with COPD. METHODS: We used data from the Clinical Practice Research Datalink, Hospital Episode Statistics and Office for National Statistics between 1 January 2004 and 31 December 2018. Ever smokers with a COPD diagnosis with minimum 3 years of baseline information were included. We compared overall using Cox regression and cause-specific mortality rates using competing risk analysis, adjusted for age, sex, deprivation, smoking status, body mass index, GOLD stage and comorbidities. Causes of death were identified using International Classification of Diseases-10 codes. RESULTS: Among 67 516 patients, 17.3% did not exacerbate during the 3-year baseline period. Mean follow-up was 4 years. Non-exacerbators were more likely to be male (63.3% vs 52.4%, p<0.001) and less often had a history of asthma (33.9% vs 43.6%, p<0.001) or FEV(1)<50% predicted (23.7 vs 31.8%) compared with exacerbators. Adjusted HR for overall mortality in non-exacerbators compared with exacerbators was 0.62 (95% CI 0.56 to 0.70) in the first year of follow-up and 0.87 (95% CI 0.83 to 0.91) thereafter. Non-exacerbating patients with COPD died less of respiratory causes than exacerbators (29.2% vs 40.3%) and more of malignancies (29.4% vs 23.4%) and cardiovascular diseases (26.2% vs 22.9%). HRs for malignant and circulatory causes of death were increased after the first year of follow-up. DISCUSSION: In this primary care cohort, non-exacerbators showed distinct clinical characteristics and lower mortality rates. Non-exacerbators were equally likely to die of respiratory, malignant or cardiovascular diseases. |
|---|
| ジャーナル名 | Thorax |
|---|
| Pubmed追加日 | 2022/11/25 |
|---|
| 投稿者 | Lenoir, Alexandra; Whittaker, Hannah; Gayle, Alicia; Jarvis, Debbie; Quint, Jennifer K |
|---|
| 組織名 | Department of Respiratory Medicine, Centre Hospitalier Universitaire Vaudois,;Lausanne, Switzerland.;Gesundheitsamt Furstenfeldbruck, Furstenfeldbruck, Germany.;National Heart and Lung Institute, Imperial College London, London, UK.;Epidemiology Department, AstraZeneca, Cambridge, UK.;National Heart and Lung Institute, Imperial College London, London, UK;j.quint@imperial.ac.uk. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/36423926/ |
|---|
